This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CONMED (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Despite weak segmental performance in fourth quarter, CONMED (CNMD) showed strength and resilience in amid a tough operating environment.
3 Top Medical Info Systems Stocks to Beat COVID-19 Resurgence Crisis
by Urmimala Biswas
Despite the severe challenges posed by the COVID-19 pandemic, higher demand for telemedicine, digital influence and AI is likely to lend support to the Zacks Medical - Information industry. OMCL, NXGN and NH are well positioned to gain.
Nextgen Healthcare (NXGN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 8.33% and 0.63%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Intuitive Surgical (ISRG) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect improvement in procedure volume.
What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
NextGen (NXGN) Solution Acts as Financial Bridge Amid COVID-19
by Zacks Equity Research
NextGen's (NXGN) cloud-based EHR platform, NextGen Office, enables specialty practices to improve their financial performance during the pandemic.
NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health
by Zacks Equity Research
FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform
NextGen (NXGN) Solutions Support COVID-19 Vaccine Distribution
by Zacks Equity Research
NextGen (NXGN) lends a hand to the nationwide rollout of COVID-19 vaccines through its robust EHR platform and integrated solutions.
3 Telemedicine Stocks to Gain in 2021 on Digital Health Boom
by Debanjana Dey
Here are a few stocks which are gaining from the booming digital healthcare space and are likely to maintain momentum in 2021, making them prudent investment choices.
NextGen's (NXGN) HDH to Facilitate Health Information Exchange
by Zacks Equity Research
NextGen's (NXGN) HDH has been chosen by HI-BRIDGE HIE for secure sharing of patient health data from multiple sources.
Is NextGen Healthcare (NXGN) a Good Value Investor Stock?
by Zacks Equity Research
Let's see if NextGen Healthcare (NXGN) stock is a good choice for value-oriented investors right now from multiple angles.
NextGen (NXGN) Reinforces Its Robust Solutions Portfolio
by Zacks Equity Research
NextGen's (NXGN) solid solutions portfolio receives further boost with the success of its Population Health tool.
Why Is Nextgen Healthcare (NXGN) Up 17.1% Since Last Earnings Report?
by Zacks Equity Research
Nextgen Healthcare (NXGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NextGen (NXGN) Strengthens Portfolio of NextGen Solutions
by Zacks Equity Research
NextGen (NXGN) continues to boost its robust portfolio of NextGen solutions with the latest adoption of NextGen Enterprise by OSMC.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
NextGen Healthcare (NXGN) Gains 8.1% Post Q2 Earnings Beat
by Zacks Equity Research
NextGen (NXGN) benefited from both its operating segments in Q2.
Nextgen Healthcare (NXGN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 50.00% and 4.99%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nextgen Healthcare (NXGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD Gets CE Mark for Point-of-Care Coronavirus Antigen Test
by Zacks Equity Research
BD (BDX) receives CE mark for its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System.
Here's Why You Should Retain Cardinal Health Stock for Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Here's Why You Should Retain OPKO Health (OPK) Stock for Now
by Zacks Equity Research
Investor confidence is high on OPKO Health (OPK), thanks to solid prospects.
3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown
by Sriparna Ghosal
These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.
Here's Why You Should Invest in LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to gain traction from its broad range of services, and strategic acquisitions and joint ventures.
Veeva Collaborates With RedHill for Coronavirus Clinical Study
by Zacks Equity Research
RedHill has adopted Veeva's (VEEV) Vault CDMS platform for the opaganib study.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.